Fluxim: Haemorrhagia Postpartum: an Implementation Study on the NVOG Guidelines and MOET Instructions

Sponsor
ZonMw: The Netherlands Organisation for Health Research and Development (Other)
Overall Status
Unknown status
CT.gov ID
NCT00928863
Collaborator
(none)
320
1
43
7.4

Study Details

Study Description

Brief Summary

The objectives of this study is first to asses to what extent the guidelines of the Dutch Society of Obstetrics and Gynaecology (NVOG) and the MOET (Management of Obstetric and Emergencies and Trauma) instructions for haemorrhagia postpartum have been implemented in current care in the Dutch practice. Second to study barriers and facilitators for guideline adherence and to develop and test a tailored implementation strategy, based on these findings.

Condition or Disease Intervention/Treatment Phase
  • Other: implementation aids

Detailed Description

The most important cause of maternal morbidity in the Netherlands is Haemorrhagia post partum (HPP), with an incidence of 5% containing 10.000 women in the Netherlands a year. Introduction of an evidence-based guideline about HPP by the Dutch society of Obstetrics and Gynaecology (NVOG) and the course Management of Obstetrics Emergencies and Trauma (MOET course) did not lead to a reduction in HPP. This implies the possibility of an incomplete implementation of both the NVOG guideline and MOET-instructions.

To evaluate the implementation of the guideline and MOET instruction in the current care, measurement of the actual care will be performed in a representative sample of 20 hospitals. Before actual care can be measured, quality indicators have to be developed regarding the process, structure and outcome based on the key recommendations from the NVOG guideline on HPP and the MOET instructions. The indicator development will be performed according to the RAND-modified Delphi method .The key recommendations from the NVOG guideline on HPP and the MOET instructions will be extracted and will be tested in two rounds among an independent panel of 12-15. The selected key recommendations will be operationalized in measurable elements. In an observational multi-centre study, actual care will be measured by video monitoring the third stage of delivery and a medical record search among 320 high risk patients for HPP in 20 hospitals. Additional information for indicator adherence will be searched in the medical records of the videotaped patients. In this manner, deviations from the indicators can be outlined. This study will provide us with reliable information about current practice in the Netherlands.

A qualitative study will be performed with the aim to discover factors in detail that are "pro" or "contra" adhering to the developed HPP-indicators by focus group interviews among groups of different involved professionals and experienced patients. Subsequently, to assess the 'prevalence' of the factors mentioned in the focus group interviews, a survey with questionnaires will be performed among all Dutch gynaecologists and midwives. The data will be analyzed to assess the most frequently mentioned barriers and facilitators.

Based on the results of step 1 and 2, a tailored implementation strategy will be developed to increase the adherence to the recommendations. The different implementation elements will be tailored to the barriers and facilitators found and will probably combine interventions directed at professional and organizational level. This strategy will be implemented and evaluated in a feasibility study. The study will be performed in 3 hospitals where the effect of the implementation strategy, the adherence to the developed indicators will be measured. A process evaluation will be performed to study the experiences of the clinicians and patients with this strategy. A cost analysis of the tested implementation strategy will take place.

Study Design

Study Type:
Observational
Anticipated Enrollment :
320 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Haemorrhagia Postpartum: an Implementation Study on the NVOG Guidelines and MOET Instructions
Study Start Date :
Jan 1, 2010
Anticipated Primary Completion Date :
Aug 1, 2013
Anticipated Study Completion Date :
Aug 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Haemorrhagia post partum

Women with a high risk for haemorrhagia post partum.

Other: implementation aids
testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals

Outcome Measures

Primary Outcome Measures

  1. actual care study: the primary outcome measure is the adherence to the quality indicators (derived from the NVOG guideline on HPP and the MOET instructions). [1 year]

  2. feasibility study: the primary outcome measure regarding effectiveness is the adherence to developed quality indicators. [1 years]

  3. barrier analysis [1 year]

    the primary outcomes in the barrier analysis are the barriers and facilitators among patients and professional regarding adherence to the quality indicators

Secondary Outcome Measures

  1. actual care study: the secondary outcome measure is the outcome (e.g. the incidence of HPP) of care. [1 year]

  2. feasibility study: the secondary outcome measures are the experiences of professionals and patients with the different elements of the implementation strategy and the changed care, and the cost of the tested strategy. [1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • woman with a high risk for haemorrhagia post partum
Exclusion Criteria:
  • woman who refuses to participate

Contacts and Locations

Locations

Site City State Country Postal Code
1 Radboud University Nijmegen Medical Centre Nijmegen Netherlands 6500 HB

Sponsors and Collaborators

  • ZonMw: The Netherlands Organisation for Health Research and Development

Investigators

  • Principal Investigator: Rosella Hermens, PhD, IQ healthcare, Radboud University Nijmegen Medical Centre

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rosella Hermens, Dr, Radboud University Medical Center
ClinicalTrials.gov Identifier:
NCT00928863
Other Study ID Numbers:
  • 80-82315-98-09003
First Posted:
Jun 26, 2009
Last Update Posted:
May 24, 2013
Last Verified:
May 1, 2013
Keywords provided by Rosella Hermens, Dr, Radboud University Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 24, 2013